AI Is More than Just Business Process Efficiency
In this forward-looking article, Saama’s Jonathan Burr, Senior VP, Clinical Platform Strategy, shows how AI is informing and re-imagining clinical trials–from the rapid development of Pfizer’s COVID-19 vaccine to the vision of a full-body digital twin.
The article debunks the common belief that AI is only good for making business processes more efficient. “A new category of technology known as Intelligent Clinical Cloud (ICC) makes AI more viable in the clinical setting than ever before,” Mr. Burr writes. “This new category of purpose-built and intelligent infrastructure is bringing sustainable transformation for drug development via AI-based clinical insights and automation platforms that achieve scale, acceleration, and repeatability across therapeutic areas.”
Though still fairly new, the application of AI to the data collected in clinical trials is yielding astounding insights:
- AI-powered chatbots harness natural language processing (NLP) and natural language understanding (NLU) to facilitate extraordinary conversational experiences for researchers with their clinical trial data.
- Increased efficiencies and cost savings are being realized related to critical outcomes, such as patient recruitment, protocol adherence, prediction of study success, patient data privacy, and the ability to leverage previously untapped sources of data.
- AI reduces the cycle time needed for researchers to process and interpret data, accelerating the industry’s ability to deliver safe and effective therapies.
According to Mr. Burr, “AI is massively effective at reducing the ‘dead time’ that bookends clinical trials, enabling sponsors to realize significant business benefits. By minimizing the study startup time prior to a patient receiving their first dose and compressing the time to FDA submission after the last study patient has been dosed, AI can positively impact sponsors’ bottom lines.”
